USPTO serial 87028341
THE HEALTHCARE DECISION COMPANY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SAUNDERS, ANDREA DAWN
- Law office
- LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with THE HEALTHCARE DECISION COMPANY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Patrick R. Delaney
PATRICK R. DELANEY DITTHAVONG & STEINER, P.C.44 CANAL CENTER PLAZA, SUITE 322ALEXANDRIA, VA 22314UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Services in the nature of providing business information featuring billing information processing relating to genetic data | ACTIVE | — |
| 042 | Conducting genetic research for scientific research purposes in connection with providing healthcare providers with personalized patient genetic-based medical analysis to enable healthcare provides to prescribe medications to their patients with genetic-based predictions as to how a patient will respond to prescribed medications; Conducting genetic research for scientific research purposes to enable healthcare providers to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects; Conducting genetic research in connection with providing healthcare providers prescription related guidance; Clinical research services for others, namely, collaborating with physicians, research organizations, patient advocacy groups, charitable organizations, and regulators to address issues related to personalized medicine; Consulting services in the fields of laboratory genetic testing or pharmacogenetics for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Genetic testing for scientific and medical research purposes to medical doctors, genetic scientists and healthcare professionals; Providing information in the field of pharmacogenetics or genetic research resources to medical doctors, genetic scientists and healthcare professionals; Providing genetic testing services for scientific research purposes and information in the field of pharmacogenetics and genetic research for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Research in the field of genetics or pharmacogenetics; Services in the nature of providing genetic testing results for scientific research purposes to medical doctors, genetic scientists and healthcare professionals; Providing temporary use of online non-downloadable computer software for controlling or managing patient record information, for the collection, editing, organizing, modifying, transmission, storage or sharing of data and information, and for scientific analysis of genetic sequences or alleles; Providing of genetic-based research information related to personalized medicine to healthcare providers, physicians, research organizations, patient advocacy groups, charitable organizations, and regulators | ACTIVE | — |
| 044 | Conducting proprietary genetic testing for medical purposes to enable healthcare providers to provide patients with personalized medical treatment, to improve both the safety and efficacy of a patient's medical treatment, and to reduce costs; Providing genetic testing results and genetic-based medical analysis to healthcare providers to enable healthcare providers for medical purposes to evaluate how a patient will metabolize medications, to predict a patient's misuse of pain medications, to predict a patient's pain perception or response to opioids, non-opioids, medical detoxification substances, or an epidural with fentanyl, or to protect a patient from NSAID and/or other drug-mediated side effects, Providing medical and prescription related guidance to healthcare providers based on the genetic testing results, genetic-based medical analysis, and known drug-drug interactions; Conducting proprietary genetic testing for medical purposes using a simple cheek swab and genomic DNA isolation processes; Providing health-related information, consultancy or advisory services for health treatment purposes; Genetic counseling; Genetic tests for health treatment purposes; Providing information, advice or data on genetic testing results for medical purposes; Health treatment services, namely, providing medical prognosis information based on collected and processed genetic data; Medical services in the nature of providing genetic testing and genetic testing results for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Proove Biosciences, Inc.
- Other trademarks owned by MYCROFT BIOANALYTICS, INC.
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named THE HEALTHCARE DECISION COMPANY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 17, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 2, 2017 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 2, 2017 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Mar 2, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 2, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 2, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 22, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 22, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 22, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 22, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 22, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| May 11, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 10, 2016 | NWAP | NEW APPLICATION ENTERED | — |